Sugi Predict

Sugi Predict / Compounds / SCHEMBL30924741

SCHEMBL30924741

SCHEMBL30924741

C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ TFPI P10646 1/20 0.57
▸ IL23R Q5VWK5 13/20 0.55
▸ NPY5R Q15761 5/20 0.54
▸ NPY1R P25929 4/20 0.54
▸ NPY4R P50391 4/20 0.54
▸ NPBWR1 P48145 1/20 0.51
▸ NPY2R P49146 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30924731 0.97 NPY4R (0.57) TFPIIL23RNPY5RNPY1RNPY4R
SCHEMBL30924745 0.97 NPY4R (0.57) TFPIIL23RNPY5RNPY1RNPY4R
SCHEMBL30924739 0.94 QRFPR (0.53) TFPIIL23RNPY5RNPY1RNPY4R
SCHEMBL30924734 0.90 IL23R (0.57) TFPIIL23RNPY5RNPY1RNPY4R
SCHEMBL30924732 0.88 TFPI (0.59) TFPIIL23RNPY5RNPY1RNPY4R
SCHEMBL7867780 0.87 NPY4R (0.58) NPY5RNPY1RNPY4RNPY2R
SCHEMBL7867793 0.87 NPY4R (0.58) NPY5RNPY1RNPY4RNPY2R
SCHEMBL31596246 0.87 IL23R (0.53) TFPIIL23RNPY5RNPY1RNPY4R
SCHEMBL30924743 0.86 TFPI (0.56) TFPIIL23RNPY5RNPY1RNPY4R
SCHEMBL30924733 0.86 TFPI (0.56) TFPIIL23R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2025-01-23 — — US disclosed
US-12162956-B2 Peptides and methods for reducing skin pigmentation GLO PHARMA, INC. (US) 2024-12-10 — — US disclosed
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2024-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R TFPI 918/4885IL23R 2274/4885NPY5R 38/4885
US-12162956-B2 Peptides and methods for reducing skin pigmentation MC1R, TYR, MC5R TFPI 918/4885IL23R 2274/4885NPY5R 38/4885
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R TFPI 918/4885IL23R 2274/4885NPY5R 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback